Channing J Der

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6104751/publications.pdf

Version: 2024-02-01

319	43,164	2322	2332
papers	citations	98 h-index	199 g-index

408	408	408	46489
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer Research, 2022, 82, 90-104.	0.9	19
2	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Advances in Cancer Research, 2022, 153, 101-130.	5.0	8
3	Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).. Journal of Clinical Oncology, 2022, 40, TPS634-TPS634.	1.6	3
4	KRASG12R-Independent Macropinocytosis in Pancreatic Cancer. Sub-Cellular Biochemistry, 2022, 98, 205-221.	2.4	3
5	Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Research, 2022, 82, 586-598.	0.9	27
6	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 762-774.	4.1	9
7	RHOA takes the RHOad less traveled to cancer. Trends in Cancer, 2022, 8, 655-669.	7.4	11
8	Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. Gut, 2021, 70, 654-665.	12.1	30
9	Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in Molecular Biology, 2021, 2262, 91-103.	0.9	2
10	G-proteins | Small GTPases. , 2021, , 488-495.		0
11	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology and Translational Science, 2021, 4, 703-712.	4.9	7
12	The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochemical Society Transactions, 2021, 49, 253-267.	3.4	29
13	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports, 2021, 35, 109291.	6.4	15
14	Engineering threshold-based selection systems. G3: Genes, Genomes, Genetics, 2021, 11, .	1.8	0
15	New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Gastroenterology, 2021, 161, 785-791.	1.3	5
16	KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Letters, 2021, 517, 66-77.	7.2	22
17	Filling in the GAPs in understanding RAS. Science, 2021, 374, 152-153.	12.6	1
18	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Journal of Biological Chemistry, 2021, 297, 101335.	3.4	14

#	Article	IF	Citations
19	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Reports, 2021, 37, 110060.	6.4	14
20	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
21	Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discovery, 2020, 10, 288-305.	9.4	91
22	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
23	RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?. Critical Reviews in Biochemistry and Molecular Biology, 2020, 55, 386-407.	5.2	27
24	Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12121-12130.	7.1	19
25	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	16.8	99
26	Binge Drinking: Macropinocytosis Promotes Tumorigenic Growth of RAS-Mutant Cancers. Trends in Biochemical Sciences, 2020, 45, 459-461.	7.5	11
27	RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Science Signaling, 2020, 13, .	3.6	62
28	Genome-wide DNA methylation analysis of KRAS mutant cell lines. Scientific Reports, 2020, 10, 10149.	3.3	7
29	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signaling, 2019, 12, .	3.6	46
30	Ultrastructure of Human Pancreatic Cancer Cells Treated with a TBK1 Inhibitor. Microscopy and Microanalysis, 2019, 25, 1284-1285.	0.4	1
31	RAS Mutations Are Not Created Equal. Cancer Discovery, 2019, 9, 696-698.	9.4	20
32	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	30.7	476
33	Blocking autophagy to starve pancreatic cancer. Nature Reviews Molecular Cell Biology, 2019, 20, 265-265.	37.0	18
34	Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers. Small GTPases, 2018, 9, 290-296.	1.6	29
35	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031435.	6.2	563
36	KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell, 2018, 34, 807-822.e7.	16.8	112

#	Article	IF	Citations
37	Computational design of chemogenetic and optogenetic split proteins. Nature Communications, 2018, 9, 4042.	12.8	75
38	RHOA mutations in cancer: Oncogenes or tumor suppressors?. , 2018, , 121-138.		0
39	Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53 -Driven Lung Adenocarcinoma. Cancer Cell, 2017, 31, 256-269.	16.8	97
40	Mutant RAS Calms Stressed-Out Cancer Cells. Developmental Cell, 2017, 40, 120-122.	7.0	5
41	A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation. Journal of Biological Chemistry, 2017, 292, 4446-4456.	3.4	36
42	Drugging RAS: Know the enemy. Science, 2017, 355, 1158-1163.	12.6	300
43	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling, 2017, 10, .	3.6	51
44	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports, 2017, 20, 999-1015.	6.4	77
45	Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS ONE, 2017, 12, e0174863.	2.5	23
46	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers, 2016, 8, 45.	3.7	147
47	Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. Cancer Research, 2016, 76, 3826-3837.	0.9	60
48	The role of wild type RAS isoforms in cancer. Seminars in Cell and Developmental Biology, 2016, 58, 60-69.	5.0	104
49	ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma. Molecular Cancer Research, 2016, 14, 1009-1018.	3.4	36
50	Protein Kinase CK2Î± Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2Î± Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Journal of Biological Chemistry, 2016, 291, 17804-17815.	3.4	28
51	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
52	Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When Itâ€™s Down. Cancer Cell, 2016, 29, 251-253.	16.8	56
53	RAS isoforms and mutations in cancer at a glance. Journal of Cell Science, 2016, 129, 1287-92.	2.0	606
54	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell, 2016, 29, 75-89.	16.8	191

#	Article	IF	Citations
55	Characterization of an Engineered Src Kinase to Study Src Signaling and Biology. Methods in Molecular Biology, 2016, 1360, 157-167.	0.9	6
56	Rho Family Proteins. , 2016, , 4076-4082.		0
57	Seeing is believing: Ras dimers observed in live cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9793-9794.	7.1	14
58	CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 152, 337-346.	2.5	22
59	Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?. Clinical Cancer Research, 2015, 21, 1819-1827.	7.0	323
60	Targeting RAS -mutant Cancers: Is ERK the Key?. Trends in Cancer, 2015, 1, 183-198.	7.4	104
61	Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases. Journal of Biological Chemistry, 2015, 290, 22851-22861.	3.4	37
62	Substrate Trapping Proteomics Reveals Targets of the Î²TrCP2/FBXW11 Ubiquitin Ligase. Molecular and Cellular Biology, 2015, 35, 167-181.	2.3	55
63	The C. elegans Chp/Wrch Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell Polarity. PLoS ONE, 2015, 10, e0133226.	2.5	11
64	Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation. Molecular Cancer Therapeutics, 2014, 13, 122-133.	4.1	18
65	Drugging the undruggable RAS: Mission Possible?. Nature Reviews Drug Discovery, 2014, 13, 828-851.	46.4	1,484
66	Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2976-2988.	4.1	85
67	Molecular Pathways: Targeting RACâ€“p21-Activated Serineâ€“Threonine Kinase Signaling in RAS-Driven Cancers. Clinical Cancer Research, 2014, 20, 4740-4746.	7.0	43
68	Ral and Rheb GTPase Activating Proteins Integrate mTOR and GTPase Signaling in Aging, Autophagy, and Tumor Cell Invasion. Molecular Cell, 2014, 53, 209-220.	9.7	112
69	KRAS: feeding pancreatic cancer proliferation. Trends in Biochemical Sciences, 2014, 39, 91-100.	7.5	546
70	P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils. Journal of Cell Science, 2014, 127, 2589-600.	2.0	50
71	RAS Genes and Cancer. , 2014, , 157-171.		0
72	Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers. , 2014, , 135-156.		5

#	Article	IF	Citations
73	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	9.4	53
74	Mechanisms of Targeted Therapy Resistance Take a De-TOR. Cancer Cell, 2013, 24, 284-286.	16.8	5
75	Mutant and Wild-type Ras: Co-conspirators in Cancer. Cancer Discovery, 2013, 3, 24-26.	9.4	15
76	Drug for an 'undruggable' protein. Nature, 2013, 497, 577-578.	27.8	45
77	The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes and Cancer, 2013, 4, 460-475.	1.9	51
78	Inhibitors of the ROCK Serine/Threonine Kinases. The Enzymes, 2013, 33 Pt A, 193-212.	1.7	6
79	Redundant Canonical and NoncanonicalCaenorhabditis elegansp21-Activated Kinase Signaling Governs Distal Tip Cell Migrations. G3: Genes, Genomes, Genetics, 2013, 3, 181-195.	1.8	16
80	TEM4 is a junctional RhoGEF required for cell-cell adhesion, monolayer integrity, and barrier function. Journal of Cell Science, 2013, 126, 3271-7.	2.0	33
81	CRL4A-FBXW5â€“mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16868-16873.	7.1	51
82	Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration. Journal of Biological Chemistry, 2013, 288, 33156-33170.	3.4	86
83	Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers. The Enzymes, 2013, 34 Pt. B, 67-106.	1.7	8
84	Preface. The Enzymes, 2013, 34 Pt. B, ix.	1.7	2
85	The RhoGEF TEM4 Regulates Endothelial Cell Migration by Suppressing Actomyosin Contractility. PLoS ONE, 2013, 8, e66260.	2.5	18
86	Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.		1
87	Differential involvement of RalA and RalB in colorectal cancer. Small GTPases, 2012, 3, 126-130.	1.6	27
88	Phosphorylation by Protein Kinase CÎ± Regulates RalB Small GTPase Protein Activation, Subcellular Localization, and Effector Utilization. Journal of Biological Chemistry, 2012, 287, 14827-14836.	3.4	31
89	The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector. Molecular and Cellular Biology, 2012, 32, 1374-1386.	2.3	78
90	ROCK1 and ROCK2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion. Cancer Research, 2012, 72, 5338-5347.	0.9	108

#	Article	IF	Citations
91	The RAF Inhibitor Paradox Revisited. Cancer Cell, 2012, 21, 147-149.	16.8	23
92	Posttranslational Lipid Modification of Rho Family Small GTPases. Methods in Molecular Biology, 2012, 827, 87-95.	0.9	22
93	Identification of a Novel Actin-Binding Domain within the Rho Guanine Nucleotide Exchange Factor TEM4. PLoS ONE, 2012, 7, e41876.	2.5	27
94	Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry, 2011, 3, 1787-1808.	2.3	349
95	RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases, 2011, 2, 202-210.	1.6	32
96	Ras Effector Switching Promotes Divergent Cell Fates in C. elegans Vulval Patterning. Developmental Cell, 2011, 20, 84-96.	7.0	56
97	Are all KRAS mutations created equal?. Lancet Oncology, The, 2011, 12, 717-718.	10.7	12
98	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nature Communications, 2011, 2, 555.	12.8	152
99	Lipid Modification of Ras Superfamily GTPases. The Enzymes, 2011, , 59-95.	1.7	6
100	The Ect2 Rho Guanine Nucleotide Exchange Factor Is Essential for Early Mouse Development and Normal Cell Cytokinesis and Migration. Genes and Cancer, 2011, 2, 932-942.	1.9	36
101	Activation and Involvement of Ral GTPases in Colorectal Cancer. Cancer Research, 2011, 71, 206-215.	0.9	74
102	The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes and Cancer, 2011, 2, 275-287.	1.9	98
103	Oncogenic Activity of Ect2 Is Regulated through Protein Kinase CÎ¹-mediated Phosphorylation. Journal of Biological Chemistry, 2011, 286, 8149-8157.	3.4	72
104	Rho Family Proteins. , 2011, , 3302-3308.		0
105	Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth. Molecular Pharmaceutics, 2010, 7, 775-785.	4.6	94
106	Personalized Medicine in Nonâ€“Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptorâ€“Targeted Therapy?. Journal of Clinical Oncology, 2010, 28, 4769-4777.	1.6	243
107	The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs. Cancer Cell, 2010, 17, 221-223.	16.8	37
108	Ras-Related Small GTPases RalA and RalB Regulate Cellular Survival After Ionizing Radiation. International Journal of Radiation Oncology Biology Physics, 2010, 78, 205-212.	0.8	23

#	Article	IF	Citations
109	Transformation by a nucleotide-activated P2Y receptor is mediated by activation of GÎ±i, GÎ±q and Rho-dependent signaling pathways. Journal of Molecular Signaling, 2010, 5, 11.	0.5	9
110	TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. Journal of Molecular Signaling, 2010, 5, 18.	0.5	18
111	Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. Journal of Molecular Signaling, 2010, 5, 2.	0.5	34
112	Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nature Reviews Cancer, 2010, 10, 842-857.	28.4	654
113	The Roles of Ras Family Small GTPases in Breast Cancer. , 2010, , 2763-2772.		2
114	Role of R-Ras in Cell Growth. , 2010, , 1753-1762.		3
115	Targeting Ras for Anticancer Drug Discovery. , 2010, , 2837-2857.		0
116	Aberrant Overexpression of the Rgl2 Ral Small GTPase-specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth through Ral-dependent and Ral-independent Mechanisms. Journal of Biological Chemistry, 2010, 285, 34729-34740.	3.4	49
117	Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA. Molecular and Cellular Biology, 2010, 30, 508-523.	2.3	100
118	A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. PLoS Medicine, 2010, 7, e1000307.	8.4	202
119	Overview of Rho GTPase History. , 2010, , 3-27.		1
120	Ras history. Small GTPases, 2010, 1, 2-27.	1.6	586
121	Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform. Journal of Biological Chemistry, 2009, 284, 6227-6240.	3.4	58
122	K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways. Molecular Cancer Research, 2009, 7, 799-808.	3.4	72
123	Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition. Journal of Molecular Signaling, 2009, 4, 5.	0.5	6
124	KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Molecular Cancer Therapeutics, 2009, 8, 834-843.	4.1	140
125	Regulation of Rnd3 localization and function by protein kinase CÎ±-mediated phosphorylation. Biochemical Journal, 2009, 424, 153-161.	3.7	53
126	Regulator of G-Protein Signaling 14 (RGS14) Is a Selective H-Ras Effector. PLoS ONE, 2009, 4, e4884.	2.5	40

#	Article	IF	Citations
127	DLCâ€1 suppresses nonâ€small cell lung cancer growth and invasion by RhoGAPâ€dependent and independent mechanisms. Molecular Carcinogenesis, 2008, 47, 326-337.	2.7	115
128	Characterization of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases. Methods in Enzymology, 2008, 439, 111-129.	1.0	94
129	Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary Oncogenesis. Molecular Cancer Research, 2008, 6, 435-445.	3.4	51
130	Effects of Structure of Rho GTPase-activating Protein DLC-1 on Cell Morphology and Migration. Journal of Biological Chemistry, 2008, 283, 32762-32770.	3.4	53
131	Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification. Journal of Biological Chemistry, 2008, 283, 25150-25163.	3.4	275
132	Tools to Study the Function of the Rasâ€Related, Estrogenâ€Regulated Growth Inhibitor in Breast Cancer. Methods in Enzymology, 2008, 439, 53-72.	1.0	7
133	Use of Caenorhabditis elegans to Evaluate Inhibitors of Ras Function In Vivo. Methods in Enzymology, 2008, 439, 425-449.	1.0	20
134	Rasâ€Driven Transformation of Human Nestinâ€Positive Pancreatic Epithelial Cells. Methods in Enzymology, 2008, 439, 451-465.	1.0	16
135	Targeting signal transduction in pancreatic cancer treatment. Expert Opinion on Therapeutic Targets, 2007, 11, 673-694.	3.4	45
136	Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth. Molecular and Cellular Biology, 2007, 27, 8003-8014.	2.3	77
137	K-Ras Promotes Growth Transformation and Invasion of Immortalized Human Pancreatic Cells by Raf and Phosphatidylinositol 3-Kinase Signaling. Cancer Research, 2007, 67, 2098-2106.	0.9	197
138	Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma. Cancer Research, 2007, 67, 1502-1512.	0.9	80
139	Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Molecular Cancer Therapeutics, 2007, 6, 2220-2229.	4.1	30
140	Auto-inhibition of the Dbl Family Protein Tim by an N-terminal Helical Motif. Journal of Biological Chemistry, 2007, 282, 13813-13823.	3.4	39
141	Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases. Journal of Biological Chemistry, 2007, 282, 35666-35678.	3.4	274
142	Stopping Ras in Its Tracks. Cell, 2007, 129, 855-857.	28.9	18
143	Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Molecular Carcinogenesis, 2007, 46, 958-970.	2.7	13
144	Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nature Structural and Molecular Biology, 2007, 14, 814-823.	8.2	83

#	Article	IF	Citations
145	Biochemical Analyses of the Wrch Atypical Rho Family GTPases. Methods in Enzymology, 2006, 406, 11-26.	1.0	23
146	Cellular Assays of Oncogene Transformation. , 2006, , 345-352.		4
147	Citron Kinase, a RhoA Effector, Enhances HIV-1 Virion Production by Modulating Exocytosis. Traffic, 2006, 7, 1643-1653.	2.7	47
148	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Current Biology, 2006, 16, 2385-2394.	3.9	212
149	Genetic and Pharmacologic Dissection of Ras Effector Utilization in Oncogenesis. Methods in Enzymology, 2006, 407, 195-217.	1.0	21
150	Characterization of RERG: An Estrogenâ€Regulated Tumor Suppressor Gene. Methods in Enzymology, 2006, 407, 513-527.	1.0	16
151	Use of Retrovirus Expression of Interfering RNA to Determine the Contribution of Activated Kâ€Ras and Ras Effector Expression to Human Tumor Cell Growth. Methods in Enzymology, 2006, 407, 556-574.	1.0	21
152	The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8173-8178.	7.1	150
153	Multiple Sequence Elements Facilitate Chp Rho GTPase Subcellular Location, Membrane Association, and Transforming Activity. Molecular Biology of the Cell, 2006, 17, 3108-3121.	2.1	34
154	Realâ€Time In Vitro Measurement of Intrinsic and Ras GAPâ€Mediated GTP Hydrolysis. Methods in Enzymology, 2006, 407, 9-22.	1.0	25
155	Ras Stories: The State of the Art. , 2006, , 1-14.		0
156	Effectors of Ras-Mediated Oncogenesis. , 2006, , 121-142.		0
157	Anti-Ras Strategies for Cancer Treatment. , 2006, , 353-380.		0
158	RHO Proteins in RAS Signaling and Transformation. , 2006, , 143-167.		0
159	GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nature Reviews Molecular Cell Biology, 2005, 6, 167-180.	37.0	1,483
160	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell, 2005, 7, 533-545.	16.8	330
161	Signaling Interplay in Ras Superfamily Function. Current Biology, 2005, 15, R563-R574.	3.9	332
162	Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 23363-23370.	3.4	87

#	Article	IF	Citations
163	Transforming Activity of the Rho Family GTPase, Wrch-1, a Wnt-regulated Cdc42 Homolog, Is Dependent on a Novel Carboxyl-terminal Palmitoylation Motif. Journal of Biological Chemistry, 2005, 280, 33055-33065.	3.4	72
164	Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12879-12884.	7.1	334
165	Critical and Distinct Roles of Amino- and Carboxyl-terminal Sequences in Regulation of the Biological Activity of the Chp Atypical Rho GTPase. Journal of Biological Chemistry, 2005, 280, 13784-13792.	3.4	59
166	Real-time in vitro measurement of GTP hydrolysis. Methods, 2005, 37, 183-189.	3.8	23
167	The Ras superfamily at a glance. Journal of Cell Science, 2005, 118, 843-846.	2.0	1,222
168	Ras Signaling, Deregulation of Gene Expression and Oncogenesis. , 2004, , 189-208.		26
169	Identification and Characterization of Rain, a Novel Ras-interacting Protein with a Unique Subcellular Localization. Journal of Biological Chemistry, 2004, 279, 22353-22361.	3.4	63
170	Requirement For C-terminal Sequences in Regulation of Ect2 Guanine Nucleotide Exchange Specificity and Transformation. Journal of Biological Chemistry, 2004, 279, 25226-25233.	3.4	49
171	p68RacGAP Is a Novel GTPase-activating Protein That Interacts with Vascular Endothelial Zinc Finger-1 and Modulates Endothelial Cell Capillary Formation. Journal of Biological Chemistry, 2004, 279, 17963-17972.	3.4	26
172	SGEF, a RhoG Guanine Nucleotide Exchange Factor that Stimulates Macropinocytosis. Molecular Biology of the Cell, 2004, 15, 3309-3319.	2.1	97
173	Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis. Cancer Research, 2004, 64, 4585-4592.	0.9	184
174	Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion. Molecular and Cellular Biology, 2004, 24, 1990-1999.	2.3	102
175	Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells. Journal of Biological Chemistry, 2004, 279, 33168-33176.	3.4	137
176	Rho-family GTPases: it's not only Rac and Rho (and I like it). Journal of Cell Science, 2004, 117, 1301-1312.	2.0	524
177	Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene, 2004, 23, 9369-9380.	5.9	157
178	Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends in Cell Biology, 2004, 14, 639-647.	7.9	274
179	Oncogenic Ras and its role in tumor cell invasion and metastasis. Seminars in Cancer Biology, 2004, 14, 105-114.	9.6	246
180	Atypical Mechanism of Regulation of the Wrch-1 Rho Family Small GTPase. Current Biology, 2004, 14, 2052-2056.	3.9	74

#	Article	IF	Citations
181	Molecular Basis for Rho GTPase Signaling Specificity. Breast Cancer Research and Treatment, 2004, 84, 61-71.	2.5	90
182	Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. International Journal of Cancer, 2004, 112, 190-199.	5.1	41
183	Interferon Regulatory Factor 7 Is Associated with Epstein-Barr Virus-Transformed Central Nervous System Lymphoma and Has Oncogenic Properties. Journal of Virology, 2004, 78, 12987-12995.	3.4	59
184	Ligand-dependent Dynamics and Intramolecular Signaling in a PDZ Domain. Journal of Molecular Biology, 2004, 335, 1105-1115.	4.2	215
185	Vav Transformation Requires Activation of Multiple GTPases and Regulation of Gene Expression. Molecular Cancer Research, 2004, 2, 702-711.	3.4	21
186	Rnd Proteins Function as RhoA Antagonists by Activating p190 RhoGAP. Current Biology, 2003, 13, 1106-1115.	3.9	222
187	Role of the pleckstrin homology domain in intersectin-L Dbl homology domain activation of Cdc42 and signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2003, 1640, 61-68.	4.1	18
188	The dark side of Ras: regulation of apoptosis. Oncogene, 2003, 22, 8999-9006.	5.9	396
189	Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews Cancer, 2003, 3, 945-951.	28.4	158
190	Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo. Journal of Biological Chemistry, 2003, 278, 35501-35507.	3.4	314
191	ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. Journal of Cell Biology, 2003, 163, 583-595.	5.2	474
192	Critical Role of the Pleckstrin Homology Domain in Dbs Signaling and Growth Regulation. Journal of Biological Chemistry, 2003, 278, 21188-21196.	3.4	27
193	Selective deficiency in protein kinase C isoenzyme expression and inadequacy in mitogen-activated protein kinase activation in cord blood T cells. Biochemical Journal, 2003, 370, 497-503.	3.7	15
194	Role of R-Ras in Cell Growth. , 2003, , 681-688.		0
195	Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Molecular Cancer Research, 2003, 1, 1077-88.	3.4	13
196	Ras Family Signaling: Therapeutic Targeting. Cancer Biology and Therapy, 2002, 1, 599-606.	3.4	191
197	Loss of Transgelin in Breast and Colon Tumors and in RIE-1 Cells by Ras Deregulation of Gene Expression through Raf-independent Pathways. Journal of Biological Chemistry, 2002, 277, 9790-9799.	3.4	118
198	RhoG Signals in Parallel with Rac1 and Cdc42. Journal of Biological Chemistry, 2002, 277, 47810-47817.	3.4	91

#	Article	IF	Citations
199	Critical Role of the Pleckstrin Homology and Cysteine-rich Domains in Vav Signaling and Transforming Activity. Journal of Biological Chemistry, 2002, 277, 39350-39359.	3.4	26
200	Involvement of Phosphatidylinositol 3-Kinase, but Not RalGDS, in TC21/R-Ras2-mediated Transformation. Journal of Biological Chemistry, 2002, 277, 9966-9975.	3.4	45
201	Role of MLK3-mediated Activation of p70 S6 Kinase in Rac1 Transformation. Journal of Biological Chemistry, 2002, 277, 4770-4777.	3.4	18
202	Cellular N-Ras Promotes Cell Survival by Downregulation of Jun N-Terminal Protein Kinase and p38. Molecular and Cellular Biology, 2002, 22, 1589-1606.	2.3	62
203	RasGRP4 Is a Novel Ras Activator Isolated from Acute Myeloid Leukemia. Journal of Biological Chemistry, 2002, 277, 30508-30514.	3.4	83
204	Critical but Distinct Roles for the Pleckstrin Homology and Cysteine-Rich Domains as Positive Modulators of Vav2 Signaling and Transformation. Molecular and Cellular Biology, 2002, 22, 2487-2497.	2.3	47
205	Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes and Development, 2002, 16, 2045-2057.	5.9	373
206	Opposing Roles of the Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades in Ras-Mediated Downregulation of Tropomyosin. Molecular and Cellular Biology, 2002, 22, 2304-2317.	2.3	64
207	XPLN, a Guanine Nucleotide Exchange Factor for RhoA and RhoB, But Not RhoC. Journal of Biological Chemistry, 2002, 277, 42964-42972.	3.4	121
208	Leukemia-Associated Rho Guanine Nucleotide Exchange Factor Promotes GÎ±q-Coupled Activation of RhoA. Molecular and Cellular Biology, 2002, 22, 4053-4061.	2.3	165
209	Role of MAP Kinases in the 1,25-Dihydroxyvitamin D3-induced Transactivation of the Rat Cytochrome P450C24 (CYP24) Promoter. Journal of Biological Chemistry, 2002, 277, 29643-29653.	3.4	96
210	Raf-independent Deregulation of p38 and JNK Mitogen-activated Protein Kinases Are Critical for Ras Transformation. Journal of Biological Chemistry, 2002, 277, 31808-31817.	3.4	73
211	Farnesyltransferase inhibitors: promises and realities. Current Opinion in Pharmacology, 2002, 2, 388-393.	3.5	124
212	Ras Proteins. , 2002, , 41-48.		0
213	Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nature Cell Biology, 2002, 4, 621-625.	10.3	288
214	Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. Nature Structural Biology, 2002, 9, 468-475.	9.7	190
215	RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 363-73.	0.8	23
216	Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Letters, 2001, 171, 1-10.	7.2	277

#	Article	IF	Citations
217	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell, 2001, 1, 63-72.	7.0	311
218	Activation of Phospholipase C-Îµ by Heterotrimeric G Protein Î²Î³-Subunits. Journal of Biological Chemistry, 2001, 276, 48257-48261.	3.4	90
219	Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis Through Distinguishable Pathways. Molecular Medicine, 2001, 7, 816-830.	4.4	88
220	[19] Analyses of TC21 /R-Ras2 signaling and biological activity. Methods in Enzymology, 2001, 333, 203-216.	1.0	4
221	Identification of ras-regulated genes by representational difference analysis. Methods in Enzymology, 2001, 332, 221-232.	1.0	4
222	Molecular basis for Rac1 recognition by guanine nucleotide exchange factors. Nature Structural Biology, 2001, 8, 1037-1041.	9.7	84
223	Rho GTPase-dependent transformation by G protein-coupled receptors. Oncogene, 2001, 20, 1547-1555.	5.9	77
224	The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene, 2001, 20, 1953-1963.	5.9	111
225	Quantitative Analysis of the Effect of Phosphoinositide Interactions on the Function of Dbl Family Proteins. Journal of Biological Chemistry, 2001, 276, 45868-45875.	3.4	83
226	Oncogenic Ras Blocks Anoikis by Activation of a Novel Effector Pathway Independent of Phosphatidylinositol 3-Kinase. Molecular and Cellular Biology, 2001, 21, 5488-5499.	2.3	109
227	The Insert Region of Rac1 Is Essential for Membrane Ruffling but Not Cellular Transformation. Molecular and Cellular Biology, 2001, 21, 2847-2857.	2.3	38
228	RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer. Journal of Biological Chemistry, 2001, 276, 42259-42267.	3.4	147
229	Leukemia-associated Rho Guanine Nucleotide Exchange Factor, a Dbl Family Protein Found Mutated in Leukemia, Causes Transformation by Activation of RhoA. Journal of Biological Chemistry, 2001, 276, 27145-27151.	3.4	112
230	Mammalian expression vectors for Ras family proteins: Generation and use of expression constructs to analyze Ras family function. Methods in Enzymology, 2001, 332, 3-36.	1.0	42
231	G2A is an oncogenic G protein-coupled receptor. Oncogene, 2000, 19, 3866-3877.	5.9	71
232	GTPase traffic control. Nature, 2000, 405, 749-751.	27.8	9
233	The Ras branch of small Gtpases: Ras family members donâ€™t fall far from the tree. Current Opinion in Cell Biology, 2000, 12, 157-165.	5.4	381
234	Understanding Ras: â€˜it ainâ€™t over â€™til itâ€™s overâ€™. Trends in Cell Biology, 2000, 10, 147-154.	7.9	739

#	Article	IF	Citations
235	Ras Inactivation of the Retinoblastoma Pathway by Distinct Mechanisms in NIH 3T3 Fibroblast and RIE-1 Epithelial Cells. Journal of Biological Chemistry, 2000, 275, 40916-40924.	3.4	28
236	Modulation of HIV-1 Replication by a Novel RhoA Effector Activity. Journal of Immunology, 2000, 164, 5369-5374.	0.8	35
237	Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions. Journal of Biological Chemistry, 2000, 275, 22172-22179.	3.4	93
238	Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia. Molecular and Cellular Biology, 2000, 20, 8655-8666.	2.3	98
239	Dissection of Ras-Dependent Signaling Pathways Controlling Aggressive Tumor Growth of Human Fibrosarcoma Cells: Evidence for a Potential Novel Pathway. Molecular and Cellular Biology, 2000, 20, 9294-9306.	2.3	47
240	Vav2 Is an Activator of Cdc42, Rac1, and RhoA. Journal of Biological Chemistry, 2000, 275, 10141-10149.	3.4	226
241	Analyses of transforming activity of rho family activators. Methods in Enzymology, 2000, 325, 425-441.	1.0	13
242	Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences. Methods in Enzymology, 2000, 327, 331-350.	1.0	18
243	Role of a Mitogen-activated Protein Kinase Pathway in the Induction of Phase II Detoxifying Enzymes by Chemicals. Journal of Biological Chemistry, 1999, 274, 27545-27552.	3.4	257
244	M-Ras/R-Ras3, a Transforming Ras Protein Regulated by Sos1, GRF1, and p120 Ras GTPase-activating Protein, Interacts with the Putative Ras Effector AF6. Journal of Biological Chemistry, 1999, 274, 23850-23857.	3.4	110
245	Integration of Rac-dependent Regulation of Cyclin D1 Transcription through a Nuclear Factor-ÎºB-dependent Pathway. Journal of Biological Chemistry, 1999, 274, 25245-25249.	3.4	260
246	Involvement of NH2-terminal Sequences in the Negative Regulation of Vav Signaling and Transforming Activity. Journal of Biological Chemistry, 1999, 274, 30410-30418.	3.4	49
247	Splice Variants of Intersectin Are Components of the Endocytic Machinery in Neurons and Nonneuronal Cells. Journal of Biological Chemistry, 1999, 274, 15671-15677.	3.4	164
248	A Non-farnesylated Ha-Ras Protein Can Be Palmitoylated and Trigger Potent Differentiation and Transformation. Journal of Biological Chemistry, 1999, 274, 1423-1431.	3.4	58
249	Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene, 1999, 18, 1807-1817.	5.9	50
250	TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene, 1999, 18, 2107-2116.	5.9	60
251	Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. Oncogene, 1999, 18, 3831-3845.	5.9	91
252	GTP Binding by Class II Transactivator: Role in Nuclear Import. Science, 1999, 285, 1402-1405.	12.6	94

#	Article	IF	Citations
253	Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factorâ€“related peptides. Gastroenterology, 1999, 117, 567-576.	1.3	37
254	Dependence of Dbl and Dbs Transformation on MEK and NF-ÎºB Activation. Molecular and Cellular Biology, 1999, 19, 7759-7770.	2.3	108
255	Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. Oncogene, 1998, 16, 2565-2573.	5.9	48
256	Increasing complexity of Ras signaling. Oncogene, 1998, 17, 1395-1413.	5.9	977
257	Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene, 1998, 17, 1415-1438.	5.9	337
258	Differential regulation of SHC proteins by nerve growth factor in sensory neurons and PC12 cells. European Journal of Neuroscience, 1998, 10, 1995-2008.	2.6	54
259	Increasing Complexity of the Ras Signaling Pathway. Journal of Biological Chemistry, 1998, 273, 19925-19928.	3.4	504
260	CD45 and Src-Related Protein Tyrosine Kinases Regulate the T Cell Response to Phorbol Esters. Biochemical and Biophysical Research Communications, 1998, 243, 444-450.	2.1	4
261	The Src Homology 2 and Phosphotyrosine Binding Domains of the ShcC Adaptor Protein Function as Inhibitors of Mitogenic Signaling by the Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 1998, 273, 20431-20437.	3.4	29
262	Transforming Potential of Dbl Family Proteins Correlates with Transcription from the Cyclin D1 Promoter but Not with Activation of Jun NH2-terminal Kinase, p38/Mpk2, Serum Response Factor, or c-Jun. Journal of Biological Chemistry, 1998, 273, 16739-16747.	3.4	84
263	Stimulation of p38 Phosphorylation and Activity by Arachidonic Acid in HeLa Cells, HL60 Promyelocytic Leukemic Cells, and Human Neutrophils. Journal of Biological Chemistry, 1998, 273, 19277-19282.	3.4	97
264	Regulation of RasGRP via a Phorbol Ester-Responsive C1 Domain. Molecular and Cellular Biology, 1998, 18, 6995-7008.	2.3	215
265	CDC42 and FGD1 Cause Distinct Signaling and Transforming Activities. Molecular and Cellular Biology, 1998, 18, 4689-4697.	2.3	59
266	Mas Oncogene Signaling and Transformation Require the Small GTP-Binding Protein Rac. Molecular and Cellular Biology, 1998, 18, 1225-1235.	2.3	73
267	The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation. Journal of Biological Chemistry, 1997, 272, 10608-10615.	3.4	158
268	14-3-3 Î¶ Negatively Regulates Raf-1 Activity by Interactions with the Raf-1 Cysteine-rich Domain. Journal of Biological Chemistry, 1997, 272, 20990-20993.	3.4	111
269	A Raf-independent Epidermal Growth Factor Receptor Autocrine Loop Is Necessary for Ras Transformation of Rat Intestinal Epithelial Cells. Journal of Biological Chemistry, 1997, 272, 18926-18931.	3.4	101
270	Oncogenic Ha-Ras-induced Signaling Activates NF-ÎºB Transcriptional Activity, Which Is Required for Cellular Transformation. Journal of Biological Chemistry, 1997, 272, 24113-24116.	3.4	344

#	Article	IF	Citations
271	p120 GAP Modulates Ras Activation of Jun Kinases and Transformation. Journal of Biological Chemistry, 1997, 272, 1677-1681.	3.4	91
272	Increasing Complexity of Ras Signal Transduction: Involvement of Rho Family Proteins. Advances in Cancer Research, 1997, 72, 57-107.	5.0	150
273	Requirement of NF-Î¹B Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras. Science, 1997, 278, 1812-1815.	12.6	527
274	R-Ras is regulated by activators and effectors distinct from those that control Ras function. Oncogene, 1997, 14, 133-143.	5.9	49
275	Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature, 1997, 390, 632-636.	27.8	683
276	Dbl family proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1332, F1-F23.	7.4	140
277	Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F51-F71.	7.4	125
278	The coupling of Î±6Î²4integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO Journal, 1997, 16, 2365-2375.	7.8	297
279	Expression Cloning of Isc, a Novel Oncogene with Structural Similarities to the Dbl Family of Guanine Nucleotide Exchange Factors. Journal of Biological Chemistry, 1996, 271, 18643-18650.	3.4	74
280	Involvement of the Switch 2 Domain of Ras in Its Interaction with Guanine Nucleotide Exchange Factors. Journal of Biological Chemistry, 1996, 271, 11076-11082.	3.4	50
281	Ras Interaction with Two Distinct Binding Domains in Raf-1 5 Be Required for Ras Transformation. Journal of Biological Chemistry, 1996, 271, 233-237.	3.4	136
282	The Mitogen-activated Protein Kinase Phosphatases PAC1, MKP-1, and MKP-2 Have Unique Substrate Specificities and Reduced Activity in Vivo toward the ERK2 sevenmaker Mutation. Journal of Biological Chemistry, 1996, 271, 6497-6501.	3.4	408
283	Identification of a Novel RalGDS-related Protein as a Candidate Effector for Ras and Rap1. Journal of Biological Chemistry, 1996, 271, 29903-29908.	3.4	62
284	Binding Specificity and Mutational Analysis of the Phosphotyrosine Binding Domain of the Brain-specific Adaptor Protein ShcC. Journal of Biological Chemistry, 1996, 271, 11787-11791.	3.4	18
285	Isolation of a NCK-associated Kinase, PRK2, an SH3-binding Protein and Potential Effector of Rho Protein Signaling. Journal of Biological Chemistry, 1996, 271, 28772-28776.	3.4	139
286	Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-kB-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation. Journal of Biological Chemistry, 1996, 271, 7992-7998.	3.4	120
287	rek, a Gene Expressed in Retina and Brain, Encodes a Receptor Tyrosine Kinase of the Axl/Tyro3 Family. Journal of Biological Chemistry, 1996, 271, 29049-29059.	3.4	28
288	Integrin-mediated Activation of MEK and Mitogen-activated Protein Kinase Is Independent of Ras. Journal of Biological Chemistry, 1996, 271, 18122-18127.	3.4	169

#	Article	IF	Citations
289	[33] Targeting proteins to membranes using signal sequences for lipid modification. Methods in Enzymology, 1995, 250, 435-454.	1.0	18
290	[6] Prenylation analysis of bacterially expressed and insect cell-expressed Ras and Ras-related proteins. Methods in Enzymology, 1995, 255, 46-60.	1.0	12
291	Guanine nucleotide exchange factors: Activators of Ras superfamily proteins. Molecular Reproduction and Development, 1995, 42, 468-476.	2.0	70
292	Guanine nucleotide exchange factors: Activators of the Ras superfamily of proteins. BioEssays, 1995, 17, 395-404.	2.5	205
293	Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Research and Treatment, 1995, 35, 133-144.	2.5	194
294	Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. Journal of Biological Chemistry, 1995, 270, 26802-26806.	3.4	319
295	Two Distinct Raf Domains Mediate Interaction with Ras. Journal of Biological Chemistry, 1995, 270, 9809-9812.	3.4	214
296	[40] Biological assays for Ras transformation. Methods in Enzymology, 1995, 255, 395-412.	1.0	176
297	[21] Analysis of Ras protein expression in mammalian cells. Methods in Enzymology, 1995, 255, 195-220.	1.0	33
298	ras Proto-Oncogene Activation in Human Malignancy. , 1995, , 17-52.		21
299	The Ras signal transduction pathway. Cancer and Metastasis Reviews, 1994, 13, 67-89.	5.9	342
300	[23] Transcriptional activation analysis of oncogene function. Methods in Enzymology, 1994, 238, 271-276.	1.0	13
301	[24] Biological assays for cellular transformation. Methods in Enzymology, 1994, 238, 277-294.	1.0	90
302	BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 1993, 75, 175-185.	28.9	634
303	Emerging concepts in the Ras superfamily of GTPâ€binding proteins. FASEB Journal, 1993, 7, 750-759.	0.5	206
304	Structure and biological effects of lipid modifications on proteins. Current Opinion in Cell Biology, 1992, 4, 629-636.	5.4	38
305	The ras superfamily of GTPâ€binding proteins: guidelines on nomenclature. FASEB Journal, 1992, 6, 2512-2513.	0.5	116
306	Alterations in transformation efficiency by the ADPRT-inhibitor 3-aminobenzamide are oncogene specific. Carcinogenesis, 1989, 10, 383-385.	2.8	11

#	Article	IF	Citations
307	Activation ofras oncogenes in chemically transformed BALB/MK-2 mouse keratinocytes. Molecular Carcinogenesis, 1989, 2, 150-158.	2.7	10
308	Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell, 1989, 59, 33-43.	28.9	424
309	Activation of cellular p21 ras by myristoylation. Biochemical Society Transactions, 1989, 17, 867-869.	3.4	6
310	The ras family of oncogenes. Cancer Treatment and Research, 1989, 47, 73-119.	0.5	18
311	Biological and biochemical properties of human rasH genes mutated at codon 61. Cell, 1986, 44, 167-176.	28.9	528
312	Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21. Cell, 1984, 37, 151-158.	28.9	147
313	Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas. Cell, 1983, 32, 201-208.	28.9	160
314	A tumor-specific membrane phosphoprotein marker in human cell hybrids. Cell, 1981, 26, 429-438.	28.9	76
315	Alterations in the extracellular matrix organization associated with the reexpression of tumorigenicity in human cell hybrids. International Journal of Cancer, 1980, 26, 451-459.	5.1	31
316	Lack of correlation between the decreased expression of cell surface LETS protein and tumorigenicity in human cell hybrids. Cell, 1978, 15, 1241-1251.	28.9	79
317	Ras-Mediated Deregulation of Gene Expression and Contribution to Oncogenesis. , 0, , 77-100.		5
318	Dlc1. The AFCS-nature Molecule Pages, 0, , .	0.2	0
319	KRAS Suppression-Induced Degradation of MYC is Antagonized by a MEK5-ERK5 Compensatory Mechanism. SSRN Electronic Journal, 0, , .	0.4	0